#Serum Biomarkers

[healixhospitals24]

Learn to interpret your liver function test results with our comprehensive guide. Understand commonly used liver tests and their implications for your health.

Do Visit: https://www.healixhospitals.com/blogs/reading-and-interpreting-your-liver-function-test-a-guide-to-commonly-used-liver-tests

[darkmaga-returns]

By GreenMedInfo Research Group

A new epidemiological study found that fluoride exposure from drinking water associates with decreased testosterone levels in young and middle-aged men.

Testosterone dropped most sharply in 18-39 year-olds based on fluoride burden. Surprisingly, in older men with higher fluoride exposure, testosterone increased with age instead of declining as expected. This complex relationship hints that fluoride may disrupt multiple hormonal pathways beyond the male reproductive axis.

A novel study reveals fluoride affects serum testosterone in a complex, age-specific manner, adding evidence that environmental toxicants may contribute to declining hormonal function in younger males.

Published in Biological Trace Element Research, the cross-sectional study examined fluoride exposure and two reproductive biomarkers, testosterone and androgen binding protein (ABP), in over 300 Chinese farmers.1 Scientists divided participants into higher and lower fluoride exposure groups based on urinary fluoride levels.

Compared to the lower exposure group, men with elevated fluoride measured significantly lower testosterone overall. This depletion was most pronounced in 18-39 year olds. Paradoxically, among higher-exposed middle aged and older men, testosterone increased slightly with age instead of undergoing the expected age-related decline.

Meanwhile, ABP remained unaffected across groups regardless of fluoride burden and age. As ABP governs testosterone transport and tissue uptake, results indicate fluoride direct

[covid-safer-hotties]

Reference archived on our website (click to see more than 1,000 open-access covid studies! Daily updates!)

This is just a pilot study, so it's hard to tell if there will be therapeutics derived from this, but it's interesting to see spa treatments pitched for releaving long-covid symptoms. This is the 3rd or 4th study in this area I've seen. Just kinda neat.

Abstract Background The long-COVID syndrome is characterised by a plethora of symptoms. Given its social and economic impact, many studies have stressed the urgency of proposing innovative strategies other than hospital settings. In this double-blind randomised case-control trial, we investigate the effects of sulfur thermal water inhalations, rich in H2S, compared to distilled water inhalations on symptoms, inflammatory markers, nasal microbiome in long-COVID patients.

Methods 30 outpatients aged 18-75, with positive diagnosis for long-COVID were randomised in two groups undergoing 12 consecutive days of inhalations. The active Group (STW) received sulfur thermal water inhalations whereas the placebo group received inhalations of sterile distilled non-pyrogenic water (SDW). Each participant was tested prior treatment at day 1 (T0), after the inhalations at day 14 (T1) and at 3 months follow-up (T2). At each time point, blood tests, nasal swabs for microbiome sampling, pulmonary functionality tests (PFTs) and pro-inflammatory marker measure were performed.

Results The scores obtained in the administered tests (6MWT, Borg score, and SGRQ) at T0, showed a significant variation in STW group, at T1 and T2. Serum cytokine levels and other inflammatory biomarkers reported a statistically significant decrease. Some specific parameters of PFT's showed ameliorations in STW group only. Changes in the STW nasopharyngeal microbiota composition were noticed, especially from T0 to T2.

Conclusions Inhalations of sulfur thermal water exerted objective and subjective improvements on subjects affected by long-COVID. Significant reduction of inflammatory markers, dyspnea scores and quantitative and qualitative changes in the nasopharyngeal microbiome were also assessed.

[fivehundredwords]

Alzheimer's Disease: biomarkers and neuroimaging markers cheatsheet for research articles

As Alzheimer's Disease (AD) research skews toward understanding the brain than the pathogenic proteins, studies exploring biomarkers and neuroimaging are hopeful toward developing a method for successful prevention of AD. A biomarker is a molecule, whose presence indicates abnormality or disease, and thus, is crucial in diagnostic procedures. Levels of certain molecules is notably altered in cerebrospinal fluid and in blood plasma, which helps in diagnosing the occurrence of AD. Neuroimaging involves the use of techniques such as magnetic resonance imaging and computed tomography to observe neuronal activity in the brain. This is good news, especially for AD, as the asymptomatic stage of the disease can be identified early enough.

Although the exact function and involvement in clinical practice is not profuse, altered concentrations of these biomarkers in plasma or cerebrospinal fluid encourage further research:

Amyloid and tau serve as the unsurprising biomarkers of AD pathology.

Neurofilament-light chain (NF-L) and visinin-like protein-1 (VILIP-1) are the most promising biomarkers of neuronal injury.

Post-synaptic protein neurogranin (Ng) and pre-synaptic proteins synaptosome-associated protein-25 (SNAP-25) and synaptotagmin-1 (Syt-1) are considered major biomarkers of synaptic injury.

Brain and CSF levels of tumor necrosis factor alpha (TNF-α) and increased levels of interleukin group of proteins (ILs) indicate intensified microglial response to neuroinflammation.

TREM2 receptor and YKL-40 glycoprotein are also reliable indicators of inflammation and impaired clearance of amyloid beta.

Heart-type fatty acid-binding protein (hFABP) could be a marker for pathology in blood vessels supplying the brain. Some vascular markers also show potential as markers of vascular injury in AD: von Willebrand factor (vWF) and monokine induced by γ-interferon (MIG, also known as CXCL-9).

Concentrations of TAR-DNA binding protein (TDP-43) in the brain and plasma and serum indicate, even contribute to, inflammation, mitochondrial dysfunction, and neuronal/synaptic injury in AD.

Neuroimaging techniques reveal structural, functional, and diffusion-related activities of the neurons. To identify them, markers are tracked in images obtained. Each marker is determined with the activity and biochemistry of the group of/individual neurons being studied.

Structural MRI will show location and severity of atrophy which can be identified in grey scale images by applying programs that create analogous color grading.

Functional MRI relies on blood oxygenation level dependent (BOLD) signal which reflects changes in blood oxygenation levels in response to neural activity.

Diffusion weighted imaging (DWI) focuses on diffusion of water molecules. A tensor model is applied to images obtained from DWI. The diffusion tensor imaging (DTI) metrics thus obtained help in studying connectivity through structural integrity of white matter tracts.

Tractography involves 3-D reconstruction of white matter as observed in DWI, which provides a more detailed look into a patient’s neural networks.

In positron emission tomography (PET), markers are identified and labelled so their features or functions can be traced during this procedure to obtain a resulting PET scan. The imaging procedure is named according to its marker: amyloid-PET, tau-PET, FDG-PET, inflammation-PET, receptor-PET.

FDA approved drugs Galantamine, Rivastigmine, and Donepezil alleviate symptoms such as memory loss and confusion in mild to moderate AD, although their effects seem to be negligible. They also cause nausea and vomiting as side effects and are not suitable for every patient. Recently approved drugs, Aducanumab and Lecanemab focus on removing accumulated amyloid. Their effectiveness is still doubted on the basis of studies finding that targeting amyloid has little to do with curbing the actual progression of the disease.

bibliography -

Tarawneh R. Biomarkers: our path towards a cure for Alzheimer disease. Biomarker insights. 2020 Nov;15:1177271920976367.

Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack Jr CR, Sperling R, Cummings J, Blennow K, O’Bryant S. The road ahead to cure Alzheimer’s disease: development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. The journal of prevention of Alzheimer's disease. 2014 Dec;1(3):181.

Medications for Alzheimer's Disease Stanford Healthcare. Accessed 21-04-2023.

[neurosurg101]

the only FDA approved biomarker for traumatic brain injury, the Brain Trauma Indicator™

The Brain Trauma Indicator™ (BTI™) works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury. Levels of these blood proteins after mTBI/concussion can help predict which patients may have intracranial lesions visible by CT scan and which won’t. Being able to predict if patients have a low probability of intracranial lesions can help health care professionals in their management of patients and the decision to perform a CT scan. Test results can be available within 3 to 4 hours.

The Brain Trauma Indicator was able to predict the presence of intracranial lesions on a CT scan 97.5 percent of the time and those who did not have intracranial lesions on a CT scan 99.6 percent of the time

A step-wise increase in biomarker concentrations over the continuum of severity from mild to severe TBI was detected. Of the two, only the neuronal biomarker UCH-L1 had the potential to detect acute intracranial lesions, as assessed by CT. Most importantly, both markers were substantially increased in TBI patients with a normal CT. Serum UCH-L1 and GFAP concentrations also strongly predicted poor outcomes

references: (1) https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-blood-test-aid-evaluation-concussion-adults?utm_medium=email&utm_source=transaction#:~:text=Press%20Announcements-,FDA%20authorizes%20marketing%20of%20first%20blood%20test%20to%20aid,evaluation%20of%20concussion%20in%20adults&text=The%20U.S.%20Food%20and%20Drug,to%20as%20concussion%2C%20in%20adults (2) https://www.cureus.com/articles/89515-advances-in-traumatic-brain-injury-biomarkers#references (3) Ghaith, H.S., Nawar, A.A., Gabra, M.D. et al. A Literature Review of Traumatic Brain Injury Biomarkers. Mol Neurobiol 59, 4141–4158 (2022). https://doi.org/10.1007/s12035-022-02822-6

[didanawisgi]

The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification

Abstract

Objective: Matrix gamma-carboxyglutamate (Gla) protein (MGP) is a vitamin K-dependent protein and a strong inhibitor of vascular calcification. Vitamin K deficiency leads to inactive uncarboxylated MGP (ucMGP), which accumulates at sites of arterial calcification. We hypothesized that as a result of ucMGP deposition around arterial calcification, the circulating fraction of ucMGP is decreased. Here we report on the development of an ucMGP assay and the potential diagnostic utility of monitoring serum ucMGP levels.

Methods and results: An ELISA-based assay was developed with which circulating ucMGP can be determined. Serum ucMGP levels were measured in healthy subjects (n = 165) and in four patient populations; patients who underwent angioplasty (n = 30), patients with aortic stenosis (n = 25), hemodialysis patients (n = 52), and calciphylaxis patients (n = 10). All four patient populations had significantly lower ucMGP levels. In angioplasty patients and in those with aortic stenosis, some overlap was observed with the control population. However, in the hemodialysis and calciphylaxis populations, virtually all subjects had ucMGP levels below the normal adult range.

Conclusion: Serum ucMGP may be used as a biomarker to identify those at risk for developing vascular calcification. This assay may become an important tool in the diagnosis of cardiovascular calcification.

[biomedres]

Is Pentraxin 3 A Marker in Pathogenesis of Metabolic Syndrome?

Is Pentraxin 3 A Marker in Pathogenesis of Metabolic Syndrome? in Biomedical Journal of Scientific & Technical Research

Pentraxin 3 (PTX3) is an acute-phase protein that is structurally similar to C-reactive protein (CRP). Macrophages, endothelial cells, and adipocytes all produce PTX3 in response to inflammatory stimuli, but hepatocytes are the main source of CRP. PTX3 could play a role in the genesis of obesity, metabolic syndrome (MetS), and CRP because obesity and MetS are chronic inflammatory diseases [1]. MetS is a group of risk factors that includes glucose intolerance, abnormal lipid profiles, hypertension, and abdominal obesity [2- 6]. Each of these factors has been linked to atherosclerosis and cardiovascular disease. The majority of current research has found a link between MetS components and inflammatory mediators such as interleukin-6, tumor necrosis factor-α, and CRP [7]. Furthermore, serum CRP levels were shown to be greater in individuals with more risk factors for MetS, and higher serum CRP levels were related to higher occurrence of cardiovascular events, reflecting the prognostic relevance of MetS severity [8]. In particular, many types of cells, including macrophages, dendritic cells, neutrophils, adipose cells, fibroblasts, and vascular endothelial cells, have been reported to produce PTX-3, a newly recognized acute-phase reactant that is structurally and functionally similar to CRP [9]. The link between MetS and PTX-3 hasn’t been well investigated, and the available evidence appears to be discordant. Several investigations have found a link between MetS components and inflammatory mediators such as interleukin-6, tumor necrosis factor-α, and CRP [7]. The hs-CRP is the most well-known and validated of these inflammatory biomarkers. Insulin resistance, endothelial dysfunction, and unfavorable cardiovascular events have all been linked to high levels of hs-CRP [10,11].

For more articles in Journals on Biomedical Sciences click here bjstr

Follow on Twitter : https://twitter.com/Biomedres01 Follow on Blogger : https://biomedres01.blogspot.com/ Like Our Pins On : https://www.pinterest.com/biomedres/

[stevenwilliam12]

NASH: Bridging the Gap Between Lifestyle Disease and Epidemic Status

Nonalcoholic Steatohepatitis (NASH) has swiftly evolved from a relatively unknown health concern to a major public health challenge, standing at the crossroads between a lifestyle-related disease and a growing global epidemic. A more severe form of nonalcoholic fatty liver disease (NAFLD), NASH is characterized by the buildup of fat in the liver accompanied by inflammation and scarring. Left unchecked, it can lead to cirrhosis, liver failure, or hepatocellular carcinoma. The rapid rise of obesity, diabetes, and metabolic syndrome worldwide has fueled the growth of NASH, making it a pressing concern in both healthcare and policy circles.

Understanding the Rising Threat of NASH

Once thought to be rare, NASH now affects an estimated 5-6% of the global population, with its prevalence rising sharply in tandem with obesity and type 2 diabetes. While previously more common in Western nations, NASH is now becoming prevalent in developing countries adopting sedentary lifestyles and Western dietary habits. By 2030, NASH is expected to become the leading cause of liver transplants in the United States, underscoring the urgency to address it through early diagnosis, lifestyle interventions, and therapeutic advancements.

Risk Factors and Disease Progression

At the heart of NASH’s rise are modifiable lifestyle factors such as poor dietary choices, physical inactivity, and obesity, which contribute to insulin resistance and metabolic dysfunction. NASH is most common among individuals with type 2 diabetes, obesity, high cholesterol, and hypertension. However, the disease often progresses silently, with many patients remaining asymptomatic until advanced stages—when liver scarring or cirrhosis has already developed. This makes early detection and management crucial to slowing disease progression.

Diagnostic Challenges

One of the main barriers to combating NASH is early detection. Since the disease is asymptomatic in its early stages, it often goes unnoticed until patients show signs of severe liver damage. Currently, the most accurate diagnostic tool is liver biopsy, but its invasive nature limits its use for routine screening. Non-invasive techniques, such as elastography and serum biomarkers, are gaining traction and offer promise for identifying NASH earlier, but widespread access to these tools remains limited. A key priority for healthcare providers is developing affordable and accessible diagnostic methods to catch NASH before it advances to irreversible stages.

Addressing the Lack of Approved Treatments

Despite the growing burden of NASH, no approved pharmacological treatments are available. Current management strategies focus on lifestyle modifications, such as weight loss, healthy eating, and exercise, which have shown to improve liver health and slow disease progression. However, these interventions are difficult to maintain, particularly for patients with chronic conditions like diabetes or obesity. The pharmaceutical industry is actively exploring new therapies targeting inflammation, fibrosis, and metabolic dysfunction, with several promising candidates in clinical trials. Combination therapies that address multiple disease mechanisms are also being investigated to improve outcomes.

Prevention as a Key Strategy

Since NASH is closely tied to lifestyle factors, prevention is essential in reducing the disease burden. Public health campaigns promoting weight management, healthy eating, and physical activity are critical to combating the root causes of NASH. Education and awareness programs can also empower patients to adopt healthier lifestyles and seek medical advice early if they are at risk. Preventive strategies must particularly focus on high-risk populations, including individuals with obesity, diabetes, and metabolic syndrome, to reduce the incidence of NASH.

Innovations on the Horizon

The next decade is poised to bring significant advancements in the fight against NASH. Ongoing research is focused on anti-fibrotic drugs, metabolic modulators, and novel liver-protective therapies. Non-invasive diagnostic tools, such as MRI-based technologies and multi-marker panels, are improving the ability to detect and monitor NASH early, allowing for personalized treatment strategies. As the pharmaceutical pipeline advances, early intervention, and combination therapies may become the gold standard in NASH management.

The Role of Collaboration in Combating NASH

Successfully addressing the NASH epidemic requires collaborative efforts across healthcare providers, pharmaceutical companies, researchers, and policymakers. Governments must allocate resources for research funding and public health initiatives to ensure that new therapies and diagnostic tools are developed and accessible. Additionally, partnerships between advocacy groups, medical professionals, and community organizations can raise awareness about NASH and its associated risks. Integrating NASH screening into routine care for at-risk populations, such as patients with obesity or type 2 diabetes, will also be essential in curbing the disease’s rise.

Conclusion

NASH has transitioned from a lifestyle-driven disease to a public health crisis, with its prevalence reaching epidemic proportions. As obesity, diabetes, and metabolic disorders continue to rise, so too will the burden of NASH unless proactive measures are taken. Although challenges remain—particularly in terms of diagnosis and treatment—advances in research, diagnostics, and prevention offer hope for improved patient outcomes. Bridging the gap between lifestyle intervention and epidemic management will require a multifaceted approach, including innovative therapies, early detection tools, and collaborative public health efforts. Only through comprehensive strategies can we slow the progression of NASH and move toward better liver health worldwide.

Latest ReportsAneurysmal Subarachnoid Hemorrhage Market | Angelman Syndrome Market | Bk Virus Infection Market | Bone And Joint Infection Market | Calcinosis Cutis Market | Cataract Surgery Complications Market | Chronic Spontaneous Urticaria Market | Chronic Venous Insufficiency Market | Complement 3 Glomerulopathy Market | Connective Tissue Disease-associated Ild Market | Excessive Daytime Sleepiness Market | H3n2 Infection Market | Hattr Market | Hepatic Encephalopathy Market | Hepatorenal Syndrome Market | Hypertriglyceridemia Market | Intracranial Arterial Diseases Market | Juvenile Rheumatoid Arthritis Market | Kawasaki Disease Market | Lateral Epicondylitis Disease Market | Multiple System Atrophy Market | Muscle Spasticity Market | Non-radiographic Axial Spondyloarthritis Market

[healixhospitals24]

Reading And Interpreting Your Liver Function Test - A Guide To Commonly Used Liver Tests

The liver is a vital organ responsible for numerous metabolic functions in the body, including detoxification, protein synthesis, and bile production. Monitoring liver health is crucial for early detection and management of liver diseases. One of the primary tools for assessing liver function is the Liver Function Test (LFT). In this guide, we will delve into the commonly used liver tests, how to interpret the results, and what they indicate about your liver health.

Understanding Liver Function Tests

Liver Function Tests (LFTs) are a group of blood tests that provide valuable insights into the health and function of the liver. These tests measure various enzymes, proteins, and substances in the blood that are indicative of liver health.

Key components of Liver Function Tests

Alanine Aminotransferase (ALT): Elevated levels suggest liver damage, commonly caused by conditions like hepatitis or fatty liver disease.

Aspartate Aminotransferase (AST): Similar to ALT, elevated AST levels indicate liver damage but may also be elevated in conditions affecting the heart or muscles.

Alkaline Phosphatase (ALP): Elevated ALP levels may suggest liver or bone disease.

Total Bilirubin: Increased levels may indicate liver dysfunction or obstruction of bile ducts.

Albumin and Total Protein: These are measures of liver synthetic function; decreased levels may suggest liver disease.

What are the causes of abnormal liver function test results?

Causes of abnormal liver function test results can vary and may indicate different underlying conditions. Some common causes include:

1. Build-up of Fat in the Liver:

* Non-alcoholic fatty liver disease (NAFLD) can lead to abnormal liver function tests, especially in overweight or obese individuals.

2. Liver Inflammation and Damage:

* Infections, toxic substances like alcohol or certain medications, and immune conditions can cause liver inflammation and subsequent abnormal test results.

3. Liver Overworking:

* When the liver is under stress from processing medicines or toxic substances like alcohol or paracetamol, it can result in abnormal liver function tests.

4. Bile Duct Blockage:

* Blockages in the bile ducts, such as by gallstones, can lead to abnormal liver function test results.

5. Liver Conditions and Diseases:

* Underlying conditions like Wilson's disease, haemochromatosis, or Gilbert's syndrome can affect liver function and result in abnormal test values.

6. Liver Injury:

* Physical injury to the liver, trauma, or presence of abscesses or tumors within the liver can cause abnormal liver function tests.

7. Medications and Supplements:

* Certain medications, over-the-counter drugs, herbal remedies, and traditional medicines can also impact liver function test results.

8. Other Factors:

* Factors like high alcohol intake, viral infections, autoimmune conditions, metabolic liver diseases, heart problems, and tumors in the liver can contribute to abnormal liver function tests.

Continue Reading: https://www.healixhospitals.com/blogs/reading-and-interpreting-your-liver-function-test-a-guide-to-commonly-used-liver-tests

[covid-safer-hotties]

Reference archived on our website (click to access over 1,000 open-access scientific studies about covid! New additions daily!)

An interesting study of diversity of covid biomarkers and what it could mean for future research

Introduction: Over the past four years, the COVID-19 pandemic has posed serious global health challenges. The severe form of disease and death resulted from the failure of immune regulatory mechanisms, closely highlighted by the dual proinflammatory cytokine and soluble immune checkpoint (sICP) storm. Identifying the individual factors impacting on disease severity, evolution and outcome, as well as any additional interconnections, have become of high scientific interest.

Methods: In this study, we evaluated a novel panel composed of ten sICPs for the predictive values of COVID-19 disease severity, mortality and Delta vs. Omicron variant infections in relation to hyperinflammatory biomarkers. The serum levels of sICPs from confirmed SARS-CoV-2 infected patients at hospital admission were determined by Luminex, and artificial neural network analysis was applied for defining the distinct patterns of molecular associations with each form of disease: mild, moderate, and severe.

Results: Notably, distinct sICP profiles characterized various stages of disease and Delta infections: while sCD40 played a central role in all defined diagrams, the differences emerged from the distribution levels of four molecules recently found and relatively less investigated (sCD30, s4-1BB, sTIM-1, sB7-H3), and their associations with various hematological and biochemical inflammatory biomarkers. The artificial neural network analysis revealed the prominent role of serum sTIM-1 and Galectin-9 levels at hospital admission in discriminating between survivors and non-survivors, as well as the role of specific anti-interleukin therapy (Tocilizumab, Anakinra) in improving survival for patients with initially high sTIM-1 levels. Furthermore, strong associations between sCD40 and Galectin-9 with suPAR defined the Omicron variant infections, while the positive match of sCD40 with sTREM-1 serum levels characterized the Delta-infected patients.

Conclusions: Of importance, this study provides a comprehensive analysis of circulatory immune factors governing the COVID-19 pathology, and identifies key roles of sCD40, sTIM-1, and Galectin-9 in predicting mortality.

[krishgen]

GENLISA™ KITa - Kyushu Lung Cancer Antigen 1 (CXorf61) Detection Kit

The GENLISA™ KITa is an advanced enzyme immunoassay designed for the precise quantification of Kyushu Lung Cancer Antigen 1 (CXorf61) in various biological fluids. This kit can be used to measure CXorf61 levels in serum, plasma, tissue homogenates, and other related samples. CXorf61, a biomarker linked to lung cancer, plays a key role in early diagnosis and monitoring of the disease. The GENLISA™ KITa offers a reliable, sensitive, and efficient solution for research and clinical applications, facilitating enhanced understanding and management of lung cancer progression and patient prognosis.

[leedsomics]

Quantitative site-specific glycoproteomics by ZenoTOF reveals glyco-signatures for breast cancer diagnosis

Intact glycopeptide characterization by mass spectrometry has proven a versatile tool for site-specific glycoproteomics analysis and biomarker screening. Here, we present a method using the ZenoTOF instrument with optimized fragmentation for intact glycopeptide identification and demonstrate its ability to analyze large-cohort glycoproteomes. From 124 clinical serum samples of breast cancer, non-cancerous diseases, and non-disease controls, a total of 6901 unique site-specific glycans on 807 glycosites of proteins were detected. Much more differences of glycoproteome were observed in breast diseases than the proteome. By employing machine learning, 15 site-specific glycans were determined as potential glyco-signatures in detecting breast cancer. The results demonstrate that our method provides a powerful tool in glycoproteomic analyses for biomarker discovery studies. http://dlvr.it/TD371G

[market-insider]

High And Ultra-high-field Nuclear Magnetic Resonance Spectroscopy Products: Understanding Size, Share, and Growth Trajectories

The global high and ultra-high-field nuclear magnetic resonance spectroscopy market size is expected to reach USD 1.03 billion by 2035, growing at a CAGR of 5.70% from 2024 to 2035, according to a new report by Grand View Research, Inc. The expansion of the market can be attributed to several factors, including increased funding and investment in biomedical research, the rising necessity for cost-effective generic medications, the broadening application, and its growing acceptance in medical diagnostics. Various regulatory agencies suggest it as a useful technique in pharmaceutical manufacturing.

According to an article published by the European Pharmaceutical Review in October 2020, regulatory agencies such as the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the U.S. FDA have issued guidance regarding the polymorphism for developing new & generic drugs. The guidance by these regulatory bodies highlighted SSNMR spectroscopy as a technique to determine the presence of multiple polymorphic forms during the identification of polymorphism in drug substances & products.

Thus, such guidance increases awareness about the wide uses of techniques during the development of generic drugs or APIs, which is expected to boost the high and ultra-high-field nuclear magnetic resonance spectroscopy market in the coming decade. Furthermore, it is useful in biomedical research due to its applications in cancer and infectious disease research. According to an article published by Griffith University in February 2021, nuclear magnetic resonance is a robust technique to determine the 3D structure of molecules, such as glycans, proteins, and DNA molecules. Such applications in the biomedical field, coupled with increasing biomedical research, are anticipated to drive market growth over the forecast period.

In addition, several studies demonstrate promising results for using nuclear magnetic resonance in metabolomics diagnosis. For instance, a study published by Dove Press in March 2022 reported that serum metabolites can serve as potential diagnostic biomarkers for tumor metastasis. H-NMR was utilized in this study to investigate serum metabolic profiles in a mouse model of colorectal cancer with lung metastasis.

Moreover, major participants are collaborating and partnering for drug discovery & development, which is expected to drive high and ultra-high-field nuclear magnetic resonance spectroscopy market growth over the forecast period. For instance, in January 2022, Evotek partnered with Lilly for drug discovery in metabolic diseases. Hence, the growing focus of key players on drug discovery & development of generic drugs & APIs, coupled with the increasing use of nuclear magnetic resonance spectroscopy in drug development, is anticipated to drive market growth in the coming decade.

For More Details or Sample Copy please visit link @: High And Ultra-high-field Nuclear Magnetic Resonance Spectroscopy Market Report

High And Ultra-high-field Nuclear Magnetic Resonance Spectroscopy Market Report Highlights

Ultra-high-field NMR Spectroscopy (600-1200 MHz) segment accounted for the largest share in frequency segment in 2023 owing to its advanced technological capabilities and expanding applications in various scientific fields

Academic research led the application segment in 2023. High and ultra-high-field NMR spectroscopy plays a key role in academic research across various disciplines, including structural biology, metabolomics, materials science, environmental science, and biomedical research

Academic led the end use segment in 2023. In various academic fields such as structural biology, metabolomics, materials science, environmental science, and biomedical research, spectroscopy holds a key position due to its ability to enhance sensitivity and specificity

Europe accounted for largest market share in 2023 attributed to the increasing demand for spectroscopy and well-established pharmaceutical & biotechnology industry in the region

The high and ultra-high-field nuclear magnetic resonance spectroscopy market is largely driven by two major players, Bruker Corporation and JEOL Ltd. These players are adopting acquisitions and other strategies to strengthen their presence in other regional markets

High And Ultra-high-field Nuclear Magnetic Resonance Spectroscopy Market Segmentation

Grand View Research has segmented the global high and ultra-high-field nuclear magnetic resonance spectroscopy market on the basis of frequency, application, end-use, and region:

Gain deeper insights on the market and receive your free copy with TOC now @: High And Ultra-high-field Nuclear Magnetic Resonance Spectroscopy Market Report

[sisiad]

miR-21, miR-29a, and miR-106b: serum and tissue biomarkers with diagnostic potential in metastatic testicular cancer

http://dlvr.it/TCYN0k